← All trials
NCT05348915
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 29, 2022
- Primary completion
- Mar 31, 2027
- Completion date
- Mar 31, 2027
- First posted
- Apr 27, 2022
- Last posted
- Nov 17, 2022
- Enrollment
- 520
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Global Blood Therapeutics, Inc.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.